drug · protein
afamelanotide acetate
Marketedupdated 6mo agoby Clinuvel Pharmaceuticals Ltd🔗 ChEMBL
Approvedcommunity read0 votes
Protein drug with a maximum clinical stage of Approval, with an approval for erythropoietic protoporphyria.
targets
Melanocyte-stimulating hormone receptor
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 20, 2033
~6.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- Jan 20, 2033method-of-use (U-2638)US 8334265
FDA exclusivities (1)
- Oct 8, 2026ODE-270Orphan Drug (7y)
News(6)
- Disc’s once-spurned rare disease drug to get a second chance at approvalMonths after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 trial and now plans to re-engage regulators.biopharma_dive · 1mo ago
- Disc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweepDisc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria w…biospace · 1mo ago
- Disc’s rebuffed rare blood disease drug sets up FDA re-do after ‘clean’ Phase 3 sweepDisc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria w…biospace · 1mo ago
- Disc spins past FDA rejection with ‘overwhelmingly positive’ phase 3 data for rare disease drugA phase 3 trial of Disc Medicine’s bitopertin has hit both co-primary endpoints and all secondary endpoints, positioning the biotech to refile for approval of the once-rejected rare disease drug ca…fiercebiotech · 1mo ago
- Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nodLeo Pharma is sticking to its mission of strengthening its pipeline in 2026, penning a $435 million deal for a rare skin disease drug from Tanabe Pharma that's awaiting an approval decision by the…fiercebiotech · 3mo ago
- Australian biopharma Clinuvel to shed up to 20% of workforce in move to USAustralian biopharma Clinuvel Pharmaceuticals is moving its headquarters to the U.S.— but up to a fifth of the company’s workforce won’t be staying for the trans-Pacific pivot.fiercebiotech · 3mo ago
Data sources
last refreshed 46m ago
Found something off?
comments(0)
5-min edit window · permanent after that